Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

8 results about "Beta-catenin" patented technology

Catenin beta-1, also known as β-catenin, is a protein that in humans is encoded by the CTNNB1 gene. β-catenin is a dual function protein, involved in regulation and coordination of cell–cell adhesion and gene transcription. In humans, the CTNNB1 protein is encoded by the CTNNB1 gene. In Drosophila, the homologous protein is called armadillo. β-catenin is a subunit of the cadherin protein complex and acts as an intracellular signal transducer in the Wnt signaling pathway. It is a member of the catenin protein family and homologous to γ-catenin, also known as plakoglobin. Beta-catenin is widely expressed in many tissues. In cardiac muscle, beta-catenin localizes to adherens junctions in intercalated disc structures, which are critical for electrical and mechanical coupling between adjacent cardiomyocytes.

Modulators of beta catenin and uses thereof

PCT designated stageWO2026112144A1Organic active ingredientsAntiinfectivesDiseaseBeta-catenin
Provided are compounds of the Formula I: or pharmaceutically acceptable salts thereof, which are useful for the modulation of beta catenin condensates and in the treatment of a variety of conditions or diseases associated therewith.
Owner:DEWPOINT THERAPEUTICS INC

Products and methods for use in treating NDP-related diseases

PendingUS20260091131A1Senses disorderAntibody mimetics/scaffoldsDiseaseFamilial exudative vitreoretinopathy
The invention relates to a construct and AAV particle comprising a wildtype NDP nucleic acid sequence or a codon-optimised NDP nucleic acid sequence. The invention further relates to products and methods for the treatment of one or more of Norrie disease, age related hearing loss, diabetic maculopathy and retinopathy, retinal neovascularisation, retinal exudation, retinopathy of prematurity (ROP), Familial exudative vitreoretinopathy (FEVR), Coats disease, and other NDP-related diseases, or other beta catenin signalling-related retinal diseases.
Owner:UCL BUSINESS LTD

Molecular marker IDO1 and application thereof in breast cancer treatment

The invention belongs to the technical field of biological medicine, and particularly relates to a molecular marker IDO1 and application thereof in breast cancer treatment. Through fat cell induction, bioinformatics analysis, small interfering RNA knock-down, tryptophan acid metabonomics, LC-MS / MS and other experimental methods, the regulation and control effect of the WNT10B-IDO1 axis on tumor-related fat cell tryptophan metabolism and the molecular mechanism of the regulation and control effect on the tumor promotion effect of the WNT10B-IDO1 axis are deeply explored. The invention discloses high expression of IDO1 in breast cancer related fat cells for the first time, and finds that breast cancer cells regulate and control the IDO1 level and tryptophan metabolism of tumor related fat cells through a WNT10B-beta catenin signal axis. By inhibiting expression of breast cancer cells WNT10B or inhibiting expression of IDO1 in tumor-associated adipocytes, tryptophan metabolic disorder of the tumor-associated adipocytes can be inhibited, dedifferentiation characteristics of the tumor-associated adipocytes are inhibited, tumor malignant phenotypes are finally inhibited, and treatment of breast cancer is realized. Therefore, the invention provides a new direction for prevention and treatment of breast cancer.
Owner:重庆医科大学国际体外诊断研究院